Tadesse Samuel, Tegene Elsah, Yilma Daniel, Yemane Tilahun, Gudina Esayas Kebede, Mossie Andualem
Department of Biomedical Sciences, Jimma University, Ethiopia.
Department of Internal Medicine, Jimma University, Ethiopia.
Heliyon. 2024 Aug 24;10(17):e36790. doi: 10.1016/j.heliyon.2024.e36790. eCollection 2024 Sep 15.
Apart from troponins, various additional biomarkers that indicate myocardial injury, inflammation, thrombosis, and other routes are being studied to improve the treatment of acute coronary syndrome (ACS). Myeloid activity has been found to be elevated in ACS, and this has sparked a great deal of interest in hematological parameters since they might offer independent insights into pathophysiology and risk assessment.
The purpose of this study was to evaluate the hematological markers' prognostic ability for all intrahospital causes of mortality in individuals with an ACS diagnosis.
A long-term cohort study based at an institution was done. At Jimma Medical Center, patients with an ACS diagnosis were progressively brought in between May 1, 2022, and October 31, 2023. Complete blood counts (CBC) and biochemical analysis were carried out. Multilevel mixed effect logistic regression was computed to evaluate the predictive competence of hematological indices on intrahospital mortality. Prognostic performance of hematological parameters was done using the ROC curve analysis.
A total of 110 patients were included, of which 99 (90 %) were diagnosed ST-elevation myocardial infarction, and 74 (67.3 %) were men. The mean age was 56 (±11) years. RDW, platelet count, and MCV were independently associated with intrahospital mortality (AOR = 1.20 with P < 0.001, AOR = 0.995 with P < 0.03, and AOR = 0.897 with P < 0.025, respectively). The predictive power of RDW-SD for intrahospital mortality was evaluated by ROC analysis, the AUC value were 0.737 (95 % CI 0.669-0.805).
This study found that red cell distribution width, mean corpuscular volume, and platelets were predictive factors for intrahospital death in patients with ACS. Thus, it is possible to predict the prognosis of an ACS patient using hematological data.
除肌钙蛋白外,正在研究各种其他可指示心肌损伤、炎症、血栓形成及其他途径的生物标志物,以改善急性冠状动脉综合征(ACS)的治疗。已发现ACS患者的骨髓活性升高,这引发了人们对血液学参数的极大兴趣,因为它们可能为病理生理学和风险评估提供独立的见解。
本研究旨在评估血液学标志物对ACS诊断患者院内所有死亡原因的预后能力。
在一家机构进行了一项长期队列研究。在吉马医疗中心,2022年5月1日至2023年10月31日期间逐步纳入ACS诊断患者。进行了全血细胞计数(CBC)和生化分析。计算多级混合效应逻辑回归以评估血液学指标对院内死亡率的预测能力。使用ROC曲线分析评估血液学参数的预后性能。
共纳入110例患者,其中99例(90%)被诊断为ST段抬高型心肌梗死,74例(67.3%)为男性。平均年龄为56(±11)岁。红细胞分布宽度(RDW)、血小板计数和平均红细胞体积(MCV)与院内死亡率独立相关(比值比[AOR]分别为1.20,P<0.001;AOR为0.995,P<0.03;AOR为0.897,P<0.025)。通过ROC分析评估RDW标准差(RDW-SD)对院内死亡率的预测能力,AUC值为0.737(95%置信区间0.669-0.805)。
本研究发现红细胞分布宽度、平均红细胞体积和血小板是ACS患者院内死亡的预测因素。因此,利用血液学数据有可能预测ACS患者的预后。